Pyrimidine-biphenyl small molecules block PD-L1 and curb breast tumors in mice
- N-acyl pyrimidine-biphenyl compounds were made as non-antibody PD-L1 blockers, since no small-molecule drug against this checkpoint is approved.
- Reporter-cell screening flagged two hits; dynamics modeling tied the better one, A6, to stable contact with D122.
- A6 weakened PD-1/PD-L1 binding in ELISA, far less potently than in cells.
- In cells it revived T cell activity and tumor killing; in syngeneic 4T1 mice it slowed tumor growth without visible systemic toxicity.
💡 Points Based on the abstract
Cell potency outrunning ELISA potency is the pattern to watch. BMS-type biphenyl PD-L1 binders act by inducing PD-L1 dimerization, and cell readouts can hide cytotoxicity, so SPR/HTRF binding, a dimerization assay and an inactive analog should come before any D122 contact optimization. The next gate is whether 4T1 efficacy holds in human PD-L1 models.